1083168-89-1 Usage
Chemical structure
A boronic acid pinacol ester with a dihydropyridine ring and a methylsulfonyl group.
Functional groups
Boronic acid, pinacol ester, dihydropyridine ring, and methylsulfonyl group.
Molecular weight
Approximately 263.13 g/mol
Appearance
A solid or crystalline compound
Solubility
Soluble in organic solvents such as dichloromethane, tetrahydrofuran, and dimethyl sulfoxide
Reactivity
Highly reactive due to the presence of the boronic acid and pinacol ester groups
Synthesis
Prepared through a multi-step synthesis involving the formation of the dihydropyridine ring and subsequent functionalization with the methylsulfonyl group
Organic synthesis
As a reagent for the construction of complex organic molecules
Pharmaceutical industry
Potential use in the development of new drugs
Materials science
For the production of advanced materials
Research and development
Its unique structure and reactivity make it a valuable tool for chemical research and development
Safety
Handle with care, as it may have potential hazards depending on its concentration and exposure conditions. Follow proper safety protocols and guidelines when working with this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1083168-89-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,1,6 and 8 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1083168-89:
(9*1)+(8*0)+(7*8)+(6*3)+(5*1)+(4*6)+(3*8)+(2*8)+(1*9)=161
161 % 10 = 1
So 1083168-89-1 is a valid CAS Registry Number.
1083168-89-1Relevant articles and documents
MODULATORS OF CFTR
-
, (2009/01/20)
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.
